HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• ASCO releases guidance on resource allocation during COVID-19 pandemic Jennifer Byrne
• Who’s driving the CARs in the race? John Sweetenham, MD, FRCP, FACP
• Trial to assess hydroxychloroquine for COVID-19 prevention during cancer treatment Jennifer R. Southall
• Community oncology practices face merger pressure, declining visits since COVID-19 Jennifer Byrne
• Use of intrauterine devices may decrease risk for ovarian cancer Jennifer Byrne
• Minor kidney dysfunction should not preclude African Americans with AML from enrolling on clinical trials Alexandra (Sasha) Todak
• Smoking cessation before lung cancer diagnosis linked to longer survival Mark Leiser
• Geriatric assessment and management improves quality of life for older adults with cancer Mark Leiser
• Medicaid expansion states see bigger declines in cancer mortality rates John DeRosier
• Videoconference intervention eases anxiety, distress among distance caregivers of patients with cancer John DeRosier
• Maintenance olaparib extends OS among women with BRCA-mutated relapsed ovarian cancer Mark Leiser
• Response to hypomethylating agents may not predict survival after HSCT for AML Mark Leiser
• Noninvasive candidiasis, viral infections common after CAR T-cell therapy John DeRosier
• Addition of atezolizumab to enzalutamide fails to extend OS in metastatic castration-resistant prostate cancer John DeRosier
• Atezolizumab plus cobimetinib improves PFS in biliary tract cancer Jennifer R. Southall
• Larotrectinib induces durable responses in TRK fusion cancers Mark Leiser
• COM701 shows antitumor activity in advanced solid tumors Jennifer R. Southall
• Younger women with gynecologic cancers at high risk for osteoporosis 1 year after treatment Jennifer R. Southall
• Pembrolizumab plus radiation effective, safe in locally advanced head and neck squamous cell carcinoma John DeRosier
• Neoadjuvant nivolumab with or without ipilimumab induces response in oral cavity cancer John DeRosier
• Prediction model shows potential for identifying cancer survivors at risk for opioid misuse Jennifer R. Southall
• Mammography screening substantially decreases risk for fatal breast cancer John DeRosier
• Health coverage mediates risk for later-stage breast cancer diagnosis among minorities Jennifer R. Southall
• Black patients at higher risk for cancer-associated venous thromboembolism John DeRosier
• Systemic anticoagulation may improve outcomes in COVID-19 hospitalizations Darlene Dobkowski, MA
• Cancer death rates continue to decline, but ‘more work ahead’ toward prevention John DeRosier
• Patients greatly underestimate scarring before Mohs surgery for facial skin cancer John DeRosier
• Iron chelation therapy effective, safe in lower-risk myelodysplastic syndrome John DeRosier
• CAR-T confers long-term quality-of-life improvement among patients with advanced lymphoma Drew Amorosi
• FDA grants orphan drug designation to multi-antigen T-cell therapy for AML
• FDA delays application for investigational CAR-T for advanced multiple myeloma
• FDA approves immunotherapy combination for first-line treatment of metastatic NSCLC
• FDA approves Rubraca for prostate cancer subset
• FDA approves ripretinib as fourth-line treatment for GIST
• FDA issues warning letters to breast implant manufacturers
• FDA approves Pomalyst as first new Kaposi sarcoma treatment in 20 years
• FDA expands Lynparza approval for gynecologic cancer
• FDA approves Retevmo for lung cancer, thyroid cancer subsets
• FDA grants orphan drug designation to HQP1351 for chronic myeloid leukemia
• FDA grants breakthrough therapy designation to Enhertu for gastric cancer subset
• FDA approves Tabrecta for certain patients with metastatic NSCLC
• FDA grants orphan drug status to MIV-818 for hepatocellular carcinoma
• FDA approval allows for subcutaneous dosing of daratumumab for myeloma
• City of Hope names pathology department chair, lymphoma center associate director
• Surgeon to lead breast oncology program at Jefferson Health
• Cleveland Clinic appoints immunotherapy center director
• OneOncology names CEO